New pharmacologic interventions to increase cardiac contractility: Challenges and opportunities

Current Opinion in Cardiology

Volumn 30, Issue 3, 2015, Pages 285-291

  Movsesian, Matthew ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

contractility; cyclic adenosine monophosphate; heart failure; phosphodiesterase inhibitors

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); CYCLIC AMP; PHOSPHODIESTERASE III INHIBITOR; CARDIOTONIC AGENT;

CALCIUM CELL LEVEL; CONGESTIVE CARDIOMYOPATHY; ENDOPLASMIC RETICULUM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; SUDDEN CARDIAC DEATH; TREATMENT OUTCOME; AGE; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; HEART CONTRACTION; HEART FAILURE; METABOLISM;

AGE FACTORS; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; CYCLIC AMP; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PHOSPHODIESTERASE 3 INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84928541198     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000165     Document Type: Review

References (74)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: A report from the American Heart Association. Circulation 2011; 123:e18-e209.
2. Roger VL. Epidemiology of heart failure. Circ Res 2013; 113:646-659.
3. Beca S, Ahmad F, Shen W, et al. Phosphodiesterase type 3a regulates basal myocardial contractility through interactingwith sarcoplasmic reticulumcalcium ATPase type 2a signaling complexes inmouse heart. Circ Res2013; 112:289-297.
4. Amsallem E, Kasparian C, Haddour G, et al. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev (Online) 2005; CD002230.
5. Ahmad F, Murata T, Shimizu K, et al. Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. Oral Dis 2015; 21:e25-e50.
6. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011; 91:651-690.
7. Taira M, Hockman SC, Calvo JC, et al. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem 1993; 268:18573-18579.
8. Meacci E, Taira M, Moos M Jr, et al. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci U S A 1992; 89:3721-3725.
9. Simmerman HK, Jones LR. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 1998; 78:921-947.
10. Takasago T, Imagawa T, Shigekawa M. Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J Biochem (Tokyo) 1989; 106:872-877.
11. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307:205-211.
12. Bristow MR, Ginsburg R, Umans V, et al. Beta 1-and beta 2-adrenergicreceptor subpopulations in nonfailing and failing human ventricularmyocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297-309.
13. Ungerer M, Parruti G, Bohm M, et al. Expression of beta-arrestins and betaadrenergic receptor kinases in the failing human heart. Circ Res 1994; 74:206-213.
14. Ungerer M, Bohm M, Elce JS, et al. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87:454-463.
15. Neumann J, Schmitz W, Scholz H, et al. Increase in myocardial G-proteins in heart failure. Lancet 1988; 2:936-937.
16. Feldman AM, Cates AE, Veazey WB, et al. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988; 82:189-197.
17. Feldman MD, Copelas L, Gwathmey JK, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987; 75:331-339.
18. Danielsen W, v der Leyen H, Meyer W, et al. Basal and isoprenalinestimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 1989; 14:171-173.
19. Bohm M, Reiger B, Schwinger RH, Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in nonfailing and failing myocardium. Cardiovasc Res 1994; 28:1713-1719.
20. Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992; 85:1046-1055.
21. Baim DS, McDowell AV, Cherniles J, et al. Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. N Engl J Med 1983; 309:748-756.
22. Benotti JR, Grossman W, Braunwald E, et al. Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med 1978; 299:1373-1377.
23. Jaski BE, Fifer MA, Wright RF, et al. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75:643-649.
24. Sinoway LS, Maskin CS, Chadwick B, et al. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 1983; 2:327-331.
25. Maskin CS, Sinoway L, Chadwick B, et al. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure. Circulation 1983; 67:1065-1070.
26. Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 1991; 121:1956-1964.
27. Monrad ES, McKay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984; 70:1030-1037.
28. Drakos SG, Kanakakis JV, Nanas S, et al. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. J Cardiovasc Pharmacol 2009; 53:157-161.
29. del Monte F, Lebeche D, Guerrero JL, et al. Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A 2004; 101:5622-5627.
30. Lyon AR, Bannister ML, Collins T, et al. Serca2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol 2011; 4:362-372.
31. Ding B, Abe J, Wei H, et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A 2005; 102:14771-14776.
32. Ding B, Abe J, Wei H, et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005; 111:2469-2476.
33. Oikawa M, Wu M, Lim S, et al. Cyclic nucleotide phosphodiesterase 3a1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol 2013; 64:11-19.
34. Dorn GW 2nd. Apoptotic and nonapoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res 2009; 81:465-473.
35. Roubille F, Tardif JC. New therapeutic targets in cardiology: heart failure and arrhythmia: HCN channels. Circulation 2013; 127:1986-1996.
36. Schmidt M, Dekker FJ, Maarsingh H. Exchange protein directly activated by cAMP (epac): A multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol Rev 2013; 65:670-709.
37. Breckler M, Berthouze M, Laurent AC, et al. Rap-linked cAMP signaling epac proteins: compartmentation, functioning and disease implications. Cell Signal 2011; 23:1257-1266.
38. Oestreich EA, Malik S, Goonasekera SA, et al. Epac and phospholipase Cepsilon regulate ca2 release in the heart by activation of protein kinase Cepsilon and calcium-calmodulin kinase II. J Biol Chem 2009; 284:1514-1522.
39. Oestreich EA, Wang H, Malik S, et al. Epac-mediated activation of phospholipase C(epsilon) plays a critical role in beta-adrenergic receptor-dependent enhancement of Ca2 mobilization in cardiac myocytes. J Biol Chem 2007; 282:5488-5495.
40. Pereira L, Metrich M, Fernandez-Velasco M, et al. The cAMP binding protein epac modulates Ca2 sparks by a Ca2/calmodulin kinase signalling pathway in rat cardiac myocytes. J Physiol 2007; 583:685-694.
41. Cazorla O, Lucas A, Poirier F, et al. The cAMP binding protein epac regulates cardiac myofilament function. Proc Natl Acad Sci U S A 2009; 106:14144-14149.
42. Morel E, Marcantoni A, Gastineau M, et al. cAMP-binding protein epac induces cardiomyocyte hypertrophy. Circ Res 2005; 97:1296-1304.
43. Pereira L, Ruiz-Hurtado G, Morel E, et al. Epac enhances excitation-transcription coupling in cardiac myocytes. J Mol Cell Cardiol 2012; 52:283-291.
44. Nakano SJ, Miyamoto SD, Movsesian M, et al. Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. Circ Heart Fail 2015; 8:57-63.
45. Hayes JS, Brunton LL, Mayer SE. Selective activation of particulate cAMPdependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem 1980; 255:5113-5119.
46. Buxton IL, Brunton LL. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 1983; 258:10233-10239.
47. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002; 295:1711-1715.
48. Mongillo M, McSorley T, Evellin S, et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 2004; 95:67-75.
49. Rochais F, Abi-Gerges A, Horner K, et al. A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res 2006; 98:1081-1088.
50. Mongillo M, Tocchetti CG, Terrin A, et al. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMPdependent pathway. Circ Res 2006; 98:226-234.
51. Stangherlin A, Gesellchen F, Zoccarato A, et al. cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholaminedependent signaling in cardiac myocytes. Circ Res 2011; 108:929-939.
52. Terrenoire C, Houslay MD, Baillie GS, Kass RS. The cardiac IKs potassium channel macromolecular complex includes the phosphodiesterase PDE4d3. J Biol Chem 2009; 284:9140-9146.
53. Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4d deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005; 123:25-35.
54. Leroy J, Richter W, Mika D, et al. Phosphodiesterase 4b in the cardiac L-type Ca(2)() channel complex regulates Ca(2)() current and protects against ventricular arrhythmias in mice. J Clin Invest 2011; 121:2651-2661.
55. Houslay MD, Baillie GS, Maurice DH. cAMP-specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 2007; 100:950-966.
56. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 2010; 35:91-100.
57. Wechsler J, Choi YH, Krall J, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3a in cardiac myocytes. J Biol Chem 2002; 277:38072-38078.
58. Kenan Y, Murata T, Shakur Y, et al. Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J Biol Chem 2000; 275:12331-12338.
59. Shakur Y, Takeda K, Kenan Y, et al. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem 2000; 275:38749-38761.
60. Han SJ, Vaccari S, Nedachi T, et al. Protein kinase B/Akt phosphorylation of PDE3a and its role in mammalian oocyte maturation. EMBO J 2006; 25:5716-5725.
61. Pozuelo Rubio M, Campbell DG, Morrice NA, Mackintosh C. Phosphodiesterase 3a binds to 14-3-3 proteins in response to PMA-induced phosphorylation of Ser428. Biochem J 2005; 392:163-172.
62. Hunter RW, Mackintosh C, Hers I. Protein kinase c-mediated phosphorylation and activation of PDE3a regulate cAMP levels in human platelets. J Biol Chem 2009; 284:12339-12348.
63. Hambleton R, Krall J, Tikishvili E, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 2005; 280:39168-39174.
64. Vandeput F, Szabo-Fresnais N, Ahmad F, et al. Selective regulation of cyclic nucleotide phosphodiesterase PDE3a isoforms. Proc Natl Acad Sci U S A 2013; 110:19778-19783.
65. Weninger S, Van Craenenbroeck K, Cameron RT, et al. Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling. Cell Signal 2014; 26:2573-2582.
66. Ahmad F, Shen W, Vandeput F, et al. Regulation of SERCA2 activity by PDE3a in human myocardium: phosphorylation-dependent interaction of PDE3a1 with SERCA2. J Biol Chem 2015. [Epub ahead of print
67. Ivanov AA, Khuri FR, Fu H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci 2013; 34:393-400.
68. Richter W, Xie M, Scheitrum C, et al. Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol 2011; 106:249-262.
69. Vandeput F, Wolda SL, Krall J, et al. Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 2007; 282:32749-32757.
70. Vandeput F, Krall J, Ockaili R, et al. cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 2009; 330:884-891.
71. Miller CL, Oikawa M, Cai Y, et al. Role of Ca2/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 2009; 105:956-964.
72. Johnson WB, Katugampola S, Able S, et al. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. Life Sci 2012; 90:328-336.
73. Nieminen MS, Altenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: An expert panel consensus. Int J Cardiol 2014; 174:360-367.
74. Orstavik O, Ata SH, Riise J, et al. Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol 2014; 171:5169-5181.